{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:25:59Z","timestamp":1794137159749,"version":"4.8.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"38","license":[{"start":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T00:00:00Z","timestamp":1535241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharmaceutical"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,7]]},"DOI":"10.1093\/eurheartj\/ehy310","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T15:09:22Z","timestamp":1526483362000},"page":"3499-3507","source":"Crossref","is-referenced-by-count":544,"title":["Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)"],"prefix":"10.1093","volume":"39","author":[{"given":"Paul M","family":"Ridker","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, USA"},{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G","family":"MacFadyen","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Thuren","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ, USA and Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Alkek Tower, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Federal University of Sao Paulo, Via Clementino, Sao Paulo SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen, Munich Heart Alliance, Lazarettstra\u00dfe 36, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Hospital, Seiryo-machi, Aoba-ku, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M","family":"Everett","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, USA"},{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Glynn","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,26]]},"reference":[{"key":"key\n\t\t\t\t20181007045249881_ehy310-B1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B4","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B5","doi-asserted-by":"crossref","first-page":"e005077.","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers, interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial","volume":"6","author":"Held","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B6","doi-asserted-by":"crossref","first-page":"e005637.","DOI":"10.1161\/JAHA.117.005637","article-title":"Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial","volume":"6","author":"Fanola","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B7","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","article-title":"Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy","volume":"286","author":"Lindmark","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0008-8749(89)90095-6","article-title":"Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1","volume":"122","author":"Loppnow","year":"1989","journal-title":"Cell Immunol"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI114498","article-title":"Proliferating or interleukin-1 activated human vascular smooth muscle cells secrete copious interleukin-6","volume":"85","author":"Loppnow","year":"1990","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B15","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomized, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B16","doi-asserted-by":"crossref","first-page":"e007490","DOI":"10.1161\/JAHA.117.007490","article-title":"Pretenders and contenders: inflammation, C-reactive protein, and interleukin-6","volume":"6","author":"Daniels","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B18","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/01.HYP.0000185463.27209.b0","article-title":"Arterial stiffness is related to systemic inflammation in essential hypertension","volume":"46","author":"Mahmud","year":"2005","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjcard.2006.07.070","article-title":"Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study)","volume":"99","author":"Lee","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/01.hjh.0000226198.44181.0c","article-title":"Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1","volume":"24","author":"Amar","year":"2006","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2337\/dc06-1793","article-title":"Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity","volume":"30","author":"Esteve","year":"2007","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B22","doi-asserted-by":"crossref","first-page":"1720.","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B23","first-page":"e174","article-title":"The CANTOS trial. One important step for clinical cardiology but a giant leap for vascular biology","volume":"11","author":"Baylis","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","article-title":"Inflammation and atherosclerosis. The end of a controversy","volume":"136","author":"Hansson","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCRESAHA.117.312200","article-title":"A gigantic proof-of-concept trial","volume":"121","author":"Iba\u00f1ez","year":"2017","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/CIRCRESAHA.117.311984","article-title":"CANTOS trial validates the inflammatory pathogenesis of atherosclerosis. Setting the stage for a new chapter in therapeutic targeting","volume":"121","author":"Weber","year":"2017","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B27","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy. Biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B28","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181007045249881_ehy310-B31","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1161\/CIRCRESAHA.114.302699","article-title":"Inflammation and its resolution as determinants of acute coronary syndromes","volume":"114","author":"Libby","year":"2014","journal-title":"Circ Res"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/38\/3499\/25944912\/ehy310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T23:56:54Z","timestamp":1571356614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/38\/3499\/5078464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,26]]},"references-count":31,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2018,8,26]]},"published-print":{"date-parts":[[2018,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy310","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,7]]},"published":{"date-parts":[[2018,8,26]]}}}